Since the synergistic effect of Aβ and tau proteins in driving the pathogenesis and progression of AD, developing an approach simultaneously reducing both Aβ and tau pathologies would be more effective than the current monotherapies targeting either Aβ or tau protein. This evidence concerns the gene MAPT and Alzheimer disease.